Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Otter, K.
Nano-drug delivery systems for an automated drug system platform.
[ Diplomarbeit/Master Thesis (UNI) ] Universität Graz; 2025.
FullText
- Autor*innen der Med Uni Graz:
- Betreuer*innen:
- El-Heliebi Amin
- Altmetrics:
- Abstract:
- Central nervous system (CNS) tumors account for approximately 0.30% of all malignancies, with a mortality rate of 0.24%. Compared to other tumor diseases, gliomas are relatively rare, but the mortality rate is disproportionately high. Glioblastomas belong to gliomas and are the most common and most aggressive tumor disease in the CNS. The average life expectancy is 15 months despite current therapies. The therapeutic treatment, due to difficulties crossing the blood-brain barrier and surgical removal, due to poor locations of glioblastomas, the treatment has always been a problem. Therefore, new methods for therapies are urgent. The main research is performed to overcome the problems in therapeutic treatment. Different administration routes, new drugs but also different delivery systems are currently investigated to overcome these problems. Therefore, numerous carrier systems are being tested, such as nanoparticles, liposomes, and micelles. Nanostructured lipid carriers represent a promising method of administration. Due to their small size, variable surface properties and good loading options, these nanoparticles are interesting candidates for various treatments of diseases with poor physical and biochemical accessibility. Their ability to cross the blood-brain barrier offers advantages in glioblastoma therapy. Nano-lipid carriers (NLC) are versatile delivery systems that can be used in a wide variety of issues. They can be used to deliver drugs, as well as genetic material or antimicrobial substances. The aim of this study is to investigate certain nanostructured lipid carriers using contactless substance transfer using the ECHO® system and to examine whether NLCs stay stable throughout the transferring process. Different fatty acids, compositions and concentrations were tested on two cell lines. Cytotoxicity pre-tests were done on the oral mucosa cell line (TR146) to examine an approximate amount of non-toxic nano-lipid carrier and then cytotoxicity and infiltration were tested on TR146 and U-87MG (glioblastoma cell line). For U-87MG cytotoxicity tests have already been performed while establishing the entire drug screening process. After the Nano-Systems have been transferred to the cell lines, the infiltration of the cells was clearly detectable. Cytotoxic effects were avoided by reducing the concentration of NLCs.